Clinical trial
Study for Patients With Chronic HCV (GT 1 or 3) Who Relapsed to Previous…
NCT00299923 · University of Hamburg-Eppendorf, Other · Unknown status
Key facts
| NCT number | NCT00299923 |
|---|---|
| Title | Study for Patients With Chronic HCV (GT 1 or 3) Who Relapsed to Previous (Peg)Interferon/ Ribavirin Combination Therapy |
| Official title | Randomized, Open-Label, Multicenter Study Examining the Effects of Duration of Treatment of PEGASYS® in Combination With Daily COPEGUS® + Amantadine in Patients With Chronic HCV After Relapse to Previous (Peg)IFN + Ribavirin Therapy. |
| Lead sponsor | University of Hamburg-Eppendorf, Other |
| Collaborators | Universitätsklinikum Hamburg-Eppendorf Hoffmann-La Roche Industry |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hepatitis C, Chronic, Relapse |
| Intervention type | Drug |
| Interventions | Peginterferon alfa-2a, Ribavirin, Amantadine |
| Enrollment | 300 |
| Start date | Nov 1, 2005 |
| First posted | Mar 7, 2006 |
| Last update posted | Mar 9, 2007 |
| Countries | Germany |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: